World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT02294929
Date of registration: 12/11/2014
Prospective Registration: No
Primary sponsor: Uppsala University Hospital
Public title: Cryoballoon Ablation in Patients With Longstanding Persistent Atrial Fibrillation CRYO-LPAF
Scientific title: Cryoballoon Ablation for Pulmonary Vein Isolation in Patients With Longstanding Persistent Atrial Fibrillation (the CRYO-LPAF Study)
Date of first enrolment: September 2013
Target sample size: 40
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT02294929
Study type:  Interventional
Study design:  Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  N/A
Countries of recruitment
Sweden
Contacts
Name:     Carina M Blomström Lundqvist, Professor
Address: 
Telephone: +46186113113
Email: carina.blomstrom.lundqvist@akademiska.se
Affiliation: 
Name:     Carina M Blomström Lundqvist, Professor
Address: 
Telephone: +46186113113
Email: carina.blomstrom.lundqvist@akademiska.se
Affiliation: 
Name:     Carina M Blomström Lundqvist, Professor
Address: 
Telephone:
Email:
Affiliation:  Department of Cardiology, Uppsala University Hospital
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Patients with longstanding persistent AF, with continuous AF of greater than one year,
as verified by ECG or telemetry strip at least one year ago, and at inclusion but with
no documentation of sinus rhythm in between.

2. Atrial fibrillation should be confirmed on at least 2 consecutive ECG supporting the
presence of AF for at least one year.

3. Patients with symptoms corresponding to at least EHRA score 2.

4. Patients, who have not previously undergone an AF ablation procedure, should have
failed at least a betablocker or class I or III antiarrhythmic drug.

Exclusion Criteria:

1. Sinus rhythm cannot be maintained for at least 1 minute after an electrical
cardioversion.

2. Congestive heart failure with NYHA class 3 or more.

3. LVEF < 35% which is not secondary to AF with inadequate rate control, according to the
judgement of the investigator.

4. LA diameter = 55 mm by echocardiography.

5. Prior AF ablation procedure of any kind.

6. AF secondary to a transient or correctable abnormality including electrolyte
imbalance, trauma, recent surgery, infection, toxic ingestion, and uncontrolled
thyroid disease as well as AF triggered by other uniform supraventricular tachycardia.

7. Contraindication to treatment with Warfarin or other anticoagulants.

8. Significant valvular disease or planned cardiac intervention.

9. Hypertrophic cardiomyopathy.

10. Recent cardiac disease states within the last 6 months; unstable angina, acute
myocardial infarction, revascularisation procedures, valve disease

11. Implantable cardioverter-defibrillator (ICD), biventricular pacing device, or Dual
chamber- or single chamber pacemaker patients who are dependent on ventricular pacing

12. Patients with intra-atrial thrombus, tumor, pulmonary embolism or another abnormality
in whom transseptal catheterization or appropriate vascular access is precluded.

13. Renal failure requiring dialysis or abnormalities of liver function tests.

14. Participant in investigational clinical or device trial.

15. Unwilling or unable to give informed consent or inaccessible for follow-up and
psychological problem that might limit compliance.

16. Active abuse of alcohol or other substance which may be causative of AF and/or might
affect compliance.



Age minimum: 30 Years
Age maximum: 70 Years
Gender: All
Health Condition(s) or Problem(s) studied
Atrial Fibrillation
Intervention(s)
Procedure: Atrial fibrillation ablation
Primary Outcome(s)
Clinical success [Time Frame: 12 months]
Secondary Outcome(s)
Role of Pulmonary vein isolation for elimination of atrial fibrillation [Time Frame: 12 months]
Prediction of freedom from AF [Time Frame: 12 months]
Left and right atrial size and function [Time Frame: 12 months]
Atrial Fibrillation burden [Time Frame: 12 months]
Quality of life [Time Frame: 12 months]
Scar tissue [Time Frame: 12 months]
Symptoms Severity Questionnaire and EHRA Symptom Classification [Time Frame: 12 months]
Catheter related complications [Time Frame: 12 months]
Rhythm assessed by % of subjects in sinus rhythm, paroxysmal AF and persistent AF [Time Frame: 12 months]
Biomarkers [Time Frame: Baseline, 6 hours, 24 hours, 12 months]
Complete freedom from AF [Time Frame: 6, 12 months]
Health economics [Time Frame: 12 months]
Secondary ID(s)
CRYO-LPAF
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Medtronic
Swedish Heart Lung Foundation
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history